CGM 097

Drug Profile

CGM 097

Alternative Names: CGM-097; NVP-CGM097

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Oct 2016 Pharmacodynamics, efficacy and adverse events data from a phase I trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Mar 2013 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) after March 2013
  • 01 Mar 2013 Phase-I clinical trials in Solid tumours (late-stage disease) in France, Germany, Singapore and Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top